Cefazolin demonstrated equivalent survival rates and lower kidney injury risks compared to standard antistaphylococcal penicillins in a new trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results